HPS Pharmacies wish to advise that iNova Pharmaceuticals (Australia) has given notice of interim procedures for the supply of:
Tambocor® (flecainide acetate)
10mg/1mL 15mL x 5 injection ampoules
Due to a change in manufacturer, and the administrative processes required to supply registered medicines, flecainide 150mg injection will only be available to patients under the Special Access Scheme (SAS) until registered stock is available in June/July 2014.
HPS Pharmacies can offer immediate supply to Category A, seriously ill patients, pending completion and submission of the Category A SAS form by the medical practitioner. Category B forms must be completed and approved by the TGA prior to any supply.
SAS flecainide is available in two presentations as follows:
SAS Tambocor Injection, 10mg/mL 15mL ampoules
SAS Flecainide Acetate, 5mg/mL 5mL syringe
There is no shortage of availability of either the injections, or flecainide oral tablets.
Please retain this notice in a prominent position, including in other related business units as a reminder for all staff members until supply returns to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or iNova Pharmaceuticals on (02) 8918 6322.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.